Primary neuroendocrine tumors (NETs) of the breast are a. Neuroendocrine Tumors of the Breast. Resident Short Review
|
|
- Rosemary Daniel
- 6 years ago
- Views:
Transcription
1 Resident Short Review Neuroendocrine Tumors of the Breast Primary neuroendocrine tumors of the breast are a rare and underrecognized subtype of mammary carcinoma. Neuroendocrine tumors of the breast occur predominately in postmenopausal women. The tumors are subclassified into well-differentiated and poorly differentiated neuroendocrine tumors, and invasive breast carcinoma with neuroendocrine features. Well-differentiated tumors show architectural similarity to carcinoids of other sites but lack characteristic neuroendocrine nuclei. Poorly differentiated neuroendocrine tumors are morphologically identical to small cell carcinoma of the lung. Neuroendocrine differentiation, seen in up to 30% of invasive breast carcinomas, is most commonly associated with mucinous and solid papillary carcinomas. The diagnosis of neuroendocrine differentiation requires expression of the neuroendocrine markers synaptophysin or chromogranin. The main differential diagnosis is a metastatic neuroendocrine tumor from an extramammary site. Neuroendocrine tumors of the breast are treated similarly to other invasive breast carcinomas. Although no consensus has been reached on the prognosis, most studies suggest a poor outcome. (Arch Pathol Lab Med. 2017;141: ; doi: /arpa RS) Primary neuroendocrine tumors (NETs) of the breast are a unique but rare subtype of breast cancer. 1 Neuroendocrine differentiation in breast carcinomas was first described by Feyrter and Hartmann 2 in 1963, based on positive silver staining in mucinous carcinomas of the breast. In 1977 Cubilla and Woodruff 3 published the first case series and coined the term primary carcinoid of the breast. Azzopardi et al 4 in 1982, based on positive modified silver staining and demonstration of neuroendocrine secretory granules on electron microscopy, referred to these tumors as argyrophilic carcinomas. It was not until 1985 that Bussolati et al 5 demonstrated positive chromogranin A staining in these tumors, providing conclusive evidence of hormone production. Sapino et al 6 in 2001 proposed the first diagnostic criteria for NETs of the breast, suggesting that tumors with greater than 50% expression of neuroendocrine markers Accepted for publication November 10, From the Department of Pathology, The University of Chicago Medicine, Chicago, Illinois (Dr Rosen); and the Department of Pathology, Rush Presbyterian St. Luke s Medical Center, Chicago, Illinois (Dr Gattuso). The authors have no relevant financial interest in the products or companies described in this article. Reprints: Lauren Elizabeth Rosen, MD, Department of Pathology, The University of Chicago Medicine, 5841 S Maryland Ave, Chicago, IL ( Lauren.Rosen@uchospitals.edu). Lauren Elizabeth Rosen, MD; Paolo Gattuso, MD (specifically chromogranin and synaptophysin) be classified as primary neuroendocrine breast carcinomas. Neuroendocrine carcinoma of the breast was endorsed as a distinct entity in the 2003 World Health Organization (WHO) Pathology and Genetics of Tumours of the Breast and Female Genital Organs, 7 and the proposed criteria from Sapino et al 6 was adopted. The 2003 WHO divided neuroendocrine carcinomas into solid neuroendocrine carcinoma, small cell/oat cell carcinoma, and large cell neuroendocrine carcinoma. 7 The term neuroendocrine carcinoma of the breast was revised to carcinomas with neuroendocrine features in the 2012 WHO Classification of Tumours of the Breast. 1 In addition, it was acknowledged that the 50% threshold for neuroendocrine marker positivity was arbitrary and this criterion was removed. 1 Carcinomas with neuroendocrine features are subclassified into 3 groups: well-differentiated neuroendocrine tumor (WD-NET), which are low-grade tumors that architecturally resemble carcinoid tumors of other sites; poorly differentiated neuroendocrine carcinoma (PD-NEC) or small cell carcinoma, which is identical to its pulmonary counterpart; and invasive breast carcinoma with neuroendocrine differentiation (IBC-NED), which is a breast carcinoma of special or no special type that demonstrates neuroendocrine differentiation by immunohistochemistry. 1 HISTOGENESIS There are 2 main theories on the histogenesis of primary NETs of the breast. The first, more controversial theory, is that these tumors evolve from neoplastic transformation of native neuroendocrine cells. 8,9 Although some authors have reported neuroendocrine cells in benign breast tissue, these findings have been largely disputed and unconfirmed. 9 The more accepted theory is that neuroendocrine differentiation arises from divergent differentiation of neoplastic stem cells into epithelial and endocrine cell lines during early carcinogenesis. 8,9 This theory is supported by the lack of benign NETs of the breast and evidence that the neuroendocrine cells are clonally related to malignant epithelial cells. 9,10 CLINICAL FEATURES The true incidence and clinical features of NETs of the breast are difficult to define, since neuroendocrine markers are not routinely used in breast cancer diagnosis and studies use varying marker positivity to define neuroendocrine differentiation. Neuroendocrine tumors of the breast account for less than 1% of breast cancers. 1 According to the current WHO classification, there are no remarkable differences in clinical presentation from other types of breast cancer. 1 Very rare cases present with hormonal hypersecretion syndromes secondary to ectopic hormone Arch Pathol Lab Med Vol 141, November 2017 Neuroendocrine Tumor of Breast Rosen & Gattuso 1577
2 production. 1 Neuroendocrine tumors of the breast occur predominately in white postmenopausal women in the sixth to seventh decade of life; however, rare cases have been reported in males Patients commonly present with stage 2 disease and have an increased propensity for regional lymph node metastases compared to those with invasive ductal carcinoma, not otherwise specified (IDC- NOS). 14 Neuroendocrine tumors of the breast have imaging characteristics that differ from IDC-NOS. By mammography, NETs are frequently heterogenously dense oval or lobulated masses with indistinct margins. 15 Neuroendocrine tumors are more likely to present as mass lesions on mammography and less likely to demonstrate calcifications than IDC-NOS. 15 The mammographic findings of NET closely mimic those of triple-negative breast cancers. 15 By ultrasonography, NETs often appear as irregular masses with indistinct borders and lack posterior enhancement. 15 PATHOLOGIC FINDINGS Tumors ranged in size from 0.8 to 13.5 cm with a mean size of 2.7 cm in one study and were significantly larger than control IDC-NOS (2.13 cm). 14,16 Grossly, tumors may be infiltrative or expansile and those with mucin production are soft and gelatinous. 16 In a retrospective review, most NETs were classified as WD-NET (155 of 284 cases, 55%), followed by PD-NEC and IBC-NED. 11 The latter entity is likely underdiagnosed, as it commonly lacks histologic features of neuroendocrine differentiation and neuroendocrine markers are not routinely performed in diagnosis. While WD-NETs tend to be of low to intermediate grade, overall NETs tend to be grade 3 lesions. 13 Well-differentiated NETs of the breast are defined by the WHO as tumors consisting of cellular solid expansile nests and trabeculae (Figure 1, A and B). 1 Other architectural patterns such as ribbons, cords, and rosettes are uncommonly present. 1 The tumor cells can be spindled, plasmacytoid, or polygonal and are separated by thin fibrovascular septae (Figure 1, C and D). 1,16 The cells may have abundant granular or clear vacuolated cytoplasm. 16 Evidence of mucin production may be present in the form of extracellular deposits or signet ring cells. 16 The nuclear features of NETs of the breast vary from the classic smooth nuclear borders and salt and pepper chromatin seen in carcinoids of other sites. Nuclei are often pleomorphic with irregular nuclear membranes, and chromatin ranges from evenly distributed with inconspicuous nucleoli to hyperchromatic or vesicular with prominent nucleoli. 16 Primary small cell carcinoma of the breast is histologically similar to its lung counterpart, characterized by densely packed hyperchromatic cells with scant cytoplasm, streaming, and crush artifact (Figure 2, A). 1,17 Nuclear molding is not a prominent feature. 17 Neuroendocrine differentiation has been demonstrated in up to 30% of invasive ductal carcinomas, and is most frequently found in mucinous carcinomas, particularly the hypercellular variant, and solid papillary carcinomas. 1 Invasive breast carcinoma with neuroendocrine differentiation is a diagnostic challenge owing to the variably present and often subtle cytologic features of neuroendocrine differentiation. Most commonly, neuroendocrine differentiation is suspected on the basis of mucinous histology or a solid papillary growth pattern. It is important to note that invasive lobular carcinoma, and in particular the alveolar variant, can also demonstrate neuroendocrine differentiation. 16 Mucinous carcinoma is histologically characterized by nests of tumor cells floating in mucin lakes with fine fibrovascular septae. 18 At least 90% of the tumor must have mucinous histology to be classified as a pure mucinous carcinoma. 18 Neuroendocrine differentiation is more frequently seen with the hypercellular variant of mucinous carcinoma, characterized by large clusters of tumor cells (Figure 2, B). 18 Solid papillary carcinoma is a rare form of breast carcinoma composed of large circumscribed nests of small monotonous polygonal to spindled cells and fine fibrovascular septae (Figure 2, C). 19 Tumor cells may form pseudorosettes around the fibrovascular cores, which can contain hyaline cartilage. 19 Neuroendocrine differentiation is present in up to 50% of cases. 19 While circumscribed, the periphery of these tumors often lacks myoepithelial cells and in the absence of definite invasive growth, solid papillary carcinoma is regarded as in situ carcinoma. 19 While WD-NETs tend to be of low to intermediate grade, overall NETs tend to be grade 3 lesions. 13 Ductal carcinoma in situ can also display neuroendocrine differentiation. Endocrine ductal carcinoma in situ (E-DCIS) is a distinct subtype of in situ carcinoma, characterized most frequently by a solid expansion of ducts with prominent fibrovascular septae and frequently, spindled cells with nuclear palisading (Figure 2, D). 20 Cytologic features are similar to those of WD-NETs. 20 Endocrine DCIS is often of low nuclear grade, with eccentric nuclei and open chromatin. Mucin production, either intracellular or extracellular, is seen in up to two-thirds of cases, and occasionally microglandular spaces or rosettes can be present. 20 ANCILLARY STUDIES Although morphologic features may suggest neuroendocrine differentiation, the diagnosis of NET requires expression of neuroendocrine markers. The most sensitive and specific immunohistochemical markers are synaptophysin and chromogranin A. 21 Neuron-specific enolase (NSE) and CD56 may show positivity but are less sensitive and specific. 21 Well-differentiated NETs and PD-NECs are more likely to show diffuse neuroendocrine marker positivity than IBC-NEDs. 22 Both chromogranin and synaptophysin expression are seen in up to 50% of PD- NECs, and NSE in 100%. 1 Neuroendocrine differentiation can also be demonstrated ultrastructurally with electron microscopy. By electron microscopy, NETs show dense core granules corresponding to chromogranin expression and clear presynaptic vesicles corresponding to synaptophysin expression. 1 Hormone markers show positivity in most WD-NETs and in greater than 50% of PD-NECs. Most NETs fall into the luminal B molecular subtype and are estrogen receptor (ER) and progesterone receptor (PR) positive, and Her2 negative. 21 Studies have shown that NETs are more likely to be ER and PR positive than IDC-NOS. Wei et al 14 demonstrated that 92% (68 of 72) of NETs were ER positive and 69% (51 of 72) were PR positive as compared to 72% (3696 of 5165) and 57% (2950 of 5165), respectively, of IDC-NOS. Poorly differentiated NECs of the breast, similar to small cell carcinomas of other sites, often show expression of thyroid transcription factor 1 (TTF1). 14 Up to 45% of poorly differentiated NETs also show expression of androgen receptor, which is often coexpressed with gross cystic disease fluid protein 15 (GCDFP15) Arch Pathol Lab Med Vol 141, November 2017 Neuroendocrine Tumor of Breast Rosen & Gattuso
3 Figure 1. A, Well-differentiated neuroendocrine tumor of the breast with a trabecular growth pattern. B, The tumor demonstrates strong expression of chromogranin A. C, Another well-differentiated neuroendocrine tumor composed of plasmacytoid cells with eccentric nuclei and a moderate amount of eosinophilic granular cytoplasm. D, The tumor cells show strong expression of synaptophysin (hematoxylin-eosin, original magnification 3200 [A and C]; original magnification 3200 [B and D]). DIFFERENTIAL DIAGNOSIS The differential diagnosis of NETs of the breast is broad and includes both benign and malignant entities. The most important differential diagnosis that must be excluded is a metastatic neuroendocrine tumor from an extramammary site. Metastases to the breast account for less than 1% of breast tumors and are most commonly hematologic or metastases from the contralateral breast. 24 Metastatic neuroendocrine tumors account for 1% to 2% of metastases to the breast. 24 Primary NETs and metastatic neuroendocrine carcinomas to the breast can show considerable morphologic overlap, and differentiation is challenging in the absence of clinical history of a prior or concurrent extramammary tumor. 24 In one review, 25 up to 44% (8 of 18) of metastatic neuroendocrine tumors to the breast were misdiagnosed as primary breast tumors. The distinction of primary from metastatic neuroendocrine tumor is critical to avoid misdiagnosis and unnecessary surgical and medical therapy in the latter. Approximately 68% (15 of 22) of primary NETs are associated with DCIS, and this is the most convincing evidence of a primary breast tumor. 24 The presence of nuclear atypia or pleomorphism in a well-differentiated tumor favors a primary NET of the breast. 24 A panel of immunohistochemical stains can prove useful in distinguishing these 2 entities. As both primary and metastatic tumors show neuroendocrine differentiation, neuroendocrine markers are not useful, nor are ER and PR, which can also show positivity in metastases. 24 The most specific markers for a breast primary are GATA3, mammaglobin, and GCDFP15, for which secondary tumors are consistently negative. 24 TTF1 shows positivity in approximately 70% (7 of 10) of metastases from the lung, and CDX2 shows positivity in 100% (5 of 5) of metastases from the gastrointestinal tract. 24 While CDX2 consistently shows negativity in primary NETs of the breast, strong TTF1 positivity can be observed in poorly differentiated breast NETs. 24 Neuroendocrine differentiation in breast carcinomas is often overlooked in routine practice. Tang et al 16 reported that neuroendocrine differentiation was missed in up to 69% (51 of 74) of breast carcinomas. Given the inconsistent neuroendocrine features in primary NETs of the breast and lack of routine testing for neuroendocrine markers, this rate of misdiagnosis is not surprising. The morphologic findings of a nested or trabecular architecture, nuclear or cytoplasmic Arch Pathol Lab Med Vol 141, November 2017 Neuroendocrine Tumor of Breast Rosen & Gattuso 1579
4 Figure 2. A, Poorly differentiated neuroendocrine carcinoma of the breast composed of densely packed cells with a high nuclear to cytoplasmic ratio and cellular streaming. B, Hypercellular variant of mucinous carcinoma of the breast composed of large clusters of tumor cells floating in mucin. C, Solid papillary carcinoma composed of solid nests of cells with delicate and hyalinized fibrovascular septae. D, Endocrine ductal carcinoma in situ consisting of a duct expanded by a solid proliferation of monotonous cells with thin fibrovascular septae and nuclear palisading (hematoxylin-eosin, original magnifications 3100 [A through C] and 3200 [D]). features of neuroendocrine differentiation, mucin production, or a solid papillary growth pattern should prompt a pathologist to order neuroendocrine markers. The misdiagnosis of NET as IDC-NOS is likely of little consequence at this time, as no consensus has been reached as to the clinical and prognostic significance of neuroendocrine differentiation. The differential diagnoses of E-DCIS and solid papillary carcinoma include usual ductal hyperplasia (UDH). 10 The solid growth pattern and streaming of cells seen in both solid papillary carcinoma and E-DCIS closely mimic UDH. Neuroendocrine marker positivity confirms a diagnosis of E- DCIS or solid papillary carcinoma, as neuroendocrine positivity is not seen in any benign breast lesion. Cytokeratin 5/6 negativity and diffuse ER positivity will also exclude UDH. Unlike UDH, solid papillary carcinomas often lack a myoepithelial cell layer and will be negative by myoepithelial (smooth muscle myosin and p63) markers. 26 TREATMENT AND PROGNOSIS There are no specific guidelines for grading, staging, or treatment of primary NETs of the breast. 1,14 The most recent WHO classification states that grading is unlikely to be clinically significant. 1 It is recommended that NETs of the breast be staged and treated similarly to conventional breast cancer. 10,14 Surgical management, like conventional breast cancer, is based on tumor location and stage. 10,14 It is recommended that patients with WD-NET and IBC-NED receive cytotoxic therapy similar to that for conventional breast cancer, and those with PD-NEC with similar protocols as for pulmonary small cell carcinoma. 10 The use of hormone therapy should be based on receptor status. 10 In 2 studies, 14,27 patients with NETs of the breast treated with endocrine therapy and radiotherapy had longer overall survival (OS) and disease-free survival than those who did not receive treatment, while patients who received chemotherapy had lower OS and disease-free survival than those who did not. The poor response to chemotherapy is hypothesized to be due to either chemoresistance commonly seen in neuroendocrine tumors of other sites, or the lack of an appropriately determined regimen. 14 No consensus has been reached on the prognosis for NETs of the breast. There are conflicting results in the literature, likely due to limited number of cases, and varying inclusion 1580 Arch Pathol Lab Med Vol 141, November 2017 Neuroendocrine Tumor of Breast Rosen & Gattuso
5 criteria. 21 Most of these studies support a poor prognosis for NETs of the breast. 10,12 14,27 Cloyd et al 11 were the first to examine prognosis for NETs by histologic subtype. Stage for stage, NETs of the breast had a worse 5-year OS than IDC- NOS. 11 Well-differentiated NETs and IBC-NED had a similar 5 year OS and disease-specific survival (DSS), while PD-NEC had a significantly poorer 5 year OS and DSS. 11 In another study, 12 neuroendocrine differentiation was found to be an independent adverse prognostic factor for OS and DSS. Neuroendocrine tumors of the breast have a significantly higher rate of local and distant recurrence than IDC- NOS. 14 CONCLUSIONS Breast carcinoma is a heterogeneous disease, composed of many different subtypes with varying clinical characteristics. Neuroendocrine tumors of the breast are a distinct subtype, first recognized by the WHO in Neuroendocrine tumors of the breast consist of 3 subtypes: WD-NET, IBC- NED, and PD-NET. As these tumors are rare, diagnosis requires exclusion of metastasis from an extramammary site. This entity is underrecognized owing to lack of consensus on the degree of neuroendocrine differentiation required for the diagnosis, and the often limited cytologic evidence of neuroendocrine differentiation. The identification of NETs depends primarily on architecture, and less so on nuclear features of neuroendocrine differentiation seen in neuroendocrine tumors of other sites. While no consensus has been reached on the clinical or prognostic significance of this entity, most large studies using updated criteria suggest a poor prognosis when compared to IDC-NOS. References 1. Bussolati G, Badve S. Carcinomas with neuroendocrine features. In: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van der Vijver MJ, eds. WHO Classification of Tumours of the Breast. Lyon, France: IARC Press; 2012: World Health Organization Classification of Tumours; vol Feyrter F, Hartmann G. Uber die carcinoide Wuchsform der Carcinoma mammae, insbesondere das Carcinoma Solidum (gelatinosum) mammae. Frankf Z Pathol. 1963;73(1): Cubilla AL, Woodruff JM. Primary carcinoid tumour of the breast: a report of eight patients. Am J Surg Pathol. 1977;4(1): Azzopardi JG, Muretto P, Goddeeris P, Eusebi V, Lauweryns JM. Carcinoid tumours of the breast: the morphological spectrum of argyrophil carcinomas. Histopathology. 1982;6(5): Bussolati G, Gugliotta P, Sapino A, Eusebi V, Lloyd RV. Chromograninreactive endocrine cells in argyrophilic carcinomas ( carcinoids ) and normal tissue of the breast. Am J Pathol. 1985;120(2): Sapino A, Papotti M, Righi L, Cassoni P, Chiusa L, Bussolati G. Clinical significance of neuroendocrine carcinoma of the breast. Ann Oncol. 2001;12(S2): S115 S Ellis IO, Schnitt SJ, Sastre-Garau X, et al. Invasive breast carcinoma. In: Tavassoli FA, Devilee P, eds. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003: World Health Organization Classification of Tumours; vol Viacava P, Castagna M, Bevilacqua G. Absence of neuroendocrine cells in fetal and adult mammary glands: are neuroendocrine breast tumours real neuroendocrine tumours? Breast. 1995;4(2): Wachter DL, Hartmann A, Beckmann MW, et al. Expression of neuroendocrine markers in different molecular subtypes of breast carcinoma. Biomed Res Int. 2014;2014: Angarita FA, Rodriquez JL, Meek E, Sanchez JO, Tawil M, Torregrosa L. Locally-advanced primary neuroendocrine carcinoma of the breast: case report and review of the literature. World J Surg Oncol. 2013;11(1): Cloyd JM, Yang RL, Allison KH, Norton JA, Hernandez-Boussard T, Wapnir IL. Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breast. Breast Cancer Res Treat. 2014;148(1): Wang J, Wei B, Albarracin CT, Hu J, Abraham SC, Wu Y. Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database. BMC Cancer. 2014; 14(1): Zhang Y, Chen Z, Bao Y, et al. Invasive neuroendocrine carcinoma of the breast: a prognostic research of 107 Chinese patients. Neoplasma. 2013;60(2): Wei B, Ding T, Xing Y, et al. Invasive neuroendocrine carcinoma of the breast: a distinct subtype of aggressive mammary carcinoma. Cancer. 2010; 116(19): Park WM, Wu Y, Wei W, Yang WT. Primary neuroendocrine carcinoma of the breast: clinical, imaging and histologic features. AJR Am J Roentgenol. 2014; 203(2):W221 W Tang F, Wei B, Tian Z, et al. Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges. Histopatholology. 2011;59(1): Shin SJ, DeLellis RA, Ying L, Rosen PP. Small cell carcinoma of the breast: a clinicopathologic and immunohistochemical study of nine patients. Am J Surg Pathol. 2000;24(9): Bussolati G, Sapino A. Mucinous carcinoma and carcinomas with signetring-cell differentiation. In: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van der Vijver MJ, eds. WHO Classification of Tumours of the Breast. Lyon, France: IARC Press; 2012: World Health Organization Classification of Tumours; vol Visscher D, Collins L, O Malley F, Badve S, Reis-Filho JS. Solid papillary carcinoma. In: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van der Vijver MJ, eds. WHO Classification of Tumours of the Breast. Lyon, France: IARC Press; 2012: World Health Organization Classification of Tumours; vol Tsang YW, Chan KC. Endocrine ductal carcinoma in situ (E-DCIS) of the breast: a form of low-grade DCIS with distinctive clinicopathologic and biologic characteristics. Am J Surg Pathol. 1996;20(8): Inno A, Bogina G, Turazza M, et al. Neuroendocrine carcinoma of the breast: current evidence and future perspectives. Oncologist. 2016;21(1): Kwon SY, Bae YK, Gu MJ, et al. Neuroendocrine differentiation correlates with hormone receptor expression and decreased survival in patients with invasive breast carcinoma. Histopathology. 2014;64(5): Righi L, Sapino A, Marchio C, Papotti M, Bussolati G. Neuroendocrine differentiation in breast cancer: established facts and unresolved problems. Semin Diagn Pathol. 2010;27(1): Mohanty SK, Kim SA, DeLair DF, et al. Comparison of metastatic neuroendocrine neoplasms to the breast and primary invasive mammary carcinomas with neuroendocrine differentiation. Mod Pathol. 2016;29(8): Perry KD, Reynolds C, Rosen DG, et al. Metastatic neuroendocrine tumour in the breast: a potential mimic of in-situ and invasive mammary carcinoma. Histopathology. 2011;59(4): Guo A, Wang Y, Rohr J, et al. Solid papillary carcinoma of the breast: a special entity needs to be distinguished from conventional invasive carcinoma avoiding over-treatment. Breast. 2016;26(1): Brask JB, Talman MM, Wielenga VT. Neuroendocrine carcinoma of the breast a pilot study of a Danish population of 240 breast cancer patients. APMIS. 2014;112(7): Arch Pathol Lab Med Vol 141, November 2017 Neuroendocrine Tumor of Breast Rosen & Gattuso 1581
Case Report. A Rare Solid Variant of Primary Neuroendocrine Carcinoma of Breast
Case Report A Rare Solid Variant of Primary Neuroendocrine Carcinoma of Breast Sahil I Panjvani*, Minesh B Gandhi, Bhawana R Chaudhari, Ankur N. Sarvaiya Department of Pathology, Smt. N.H.L. Municipal
More informationNEUROENDOCRINE DIFFERENTIATED BREAST CARCINOMA
+ NEUROENDOCRINE DIFFERENTIATED BREAST CARCINOMA + INTRODUCTION + NEUROENDOCRINE FEATURES IN BREAST CARCINOMA Incidence of 2-5% Seen in various histopathological types of breast carcinoma Seen in both
More informationCase Report Primary Neuroendocrine Carcinoma of the Breast: Histopathological Criteria, Prognostic Factors, and Review of the Literature
Case Reports in Pathology Volume 2016, Article ID 6762085, 4 pages http://dx.doi.org/10.1155/2016/6762085 Case Report Primary Neuroendocrine Carcinoma of the Breast: Histopathological Criteria, Prognostic
More informationPapillary Lesions of the Breast A Practical Approach to Diagnosis. (Arch Pathol Lab Med. 2016;140: ; doi: /arpa.
Papillary Lesions of the Breast A Practical Approach to Diagnosis (Arch Pathol Lab Med. 2016;140:1052 1059; doi: 10.5858/arpa.2016-0219-RA) Papillary lesions of the breast Span the spectrum of benign,
More informationNeuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical parameters
& 2004 USCAP, Inc All rights reserved 0893-3952/04 $25.00 www.modernpathology.org Neuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical
More informationPapillary Lesions of the Breast: WHO Update
Papillary Lesions of the Breast: WHO Update Stuart J. Schnitt, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA, USA Papillary Lesions of the Breast
More informationBasement membrane in lobule.
Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.
More informationRespiratory Tract Cytology
Respiratory Tract Cytology 40 th European Congress of Cytology Liverpool, UK Momin T. Siddiqui M.D. Professor of Pathology and Laboratory Medicine Director of Cytopathology Emory University Hospital, Atlanta,
More informationTitle malignancy. Issue Date Right 209, 12, (2013)
NAOSITE: Nagasaki University's Ac Title Author(s) A case of intracystic apocrine papi malignancy Hayashi, Hiroko; Ohtani, Hiroshi; Y Citation Pathology - Research and Practice, Issue Date 2013-12 URL Right
More informationCase Report Synchronous Bilateral Solid Papillary Carcinomas of the Breast
Case Reports in Surgery Volume 2013, Article ID 812129, 4 pages http://dx.doi.org/10.1155/2013/812129 Case Report Synchronous Bilateral Solid Papillary Carcinomas of the Breast Noriko Yoshimura, 1 Shigeru
More informationInvasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database
Wang et al. BMC Cancer 2014, 14:147 RESEARCH ARTICLE Open Access Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database
More informationUniversity of Zurich. Histology and Immunophenotype of Invasive Lobular Breast Cancer. Daily Practice and Pitfalls. Zurich Open Repository and Archive
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2009 Histology and Immunophenotype of Invasive Lobular Breast Cancer. Daily Practice
More information04/10/2018. Intraductal Papillary Neoplasms Of Breast INTRADUCTAL PAPILLOMA
Intraductal Papillary Neoplasms Of Breast Savitri Krishnamurthy MD Professor of Pathology Deputy Division Head The University of Texas MD Anderson Cancer Center 25 th Annual Seminar in Pathology Pittsburgh,
More information1 NORMAL HISTOLOGY AND METAPLASIAS
1 NORMAL HISTOLOGY AND METAPLASIAS, MD Anatomy and Histology 1 Metaplasias 2 ANATOMY AND HISTOLOGY The female breast is composed of a branching duct system, which begins at the nipple with the major lactiferous
More informationTriple Negative Breast Cancer
Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional
More informationDIAGNOSTIC DILEMMA. Case Reports Clinical history. Materials and Methods
DIAGNOSTIC DILEMMA A Metastatic Renal Carcinoid Tumor Presenting as Breast Mass: A Diagnostic Dilemma Farnaz Hasteh, M.D., 1 Robert Pu, M.D., Ph.D., 2 and Claire W. Michael, M.D. 2 * We present clinicopathological
More informationProliferative Epithelial lesions of the Breast. Sami Shousha, MD, FRCPath Charing Cross Hospital & Imperial College, London
Proliferative Epithelial lesions of the Breast Sami Shousha, MD, FRCPath Charing Cross Hospital & Imperial College, London Amman, November2013 Proliferative Epithelial Lesions of the Breast Usual type
More informationHistological Type. Morphological and Molecular Typing of breast Cancer. Nottingham Tenovus Primary Breast Cancer Study. Survival (%) Ian Ellis
Morphological and Molecular Typing of breast Cancer Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology, Nottingham University Hospitals NHS Trust Histological Type
More informationCarcinoma mammario: le istologie non frequenti. Valentina Guarneri Università di Padova IOV-IRCCS
Carcinoma mammario: le istologie non frequenti Valentina Guarneri Università di Padova IOV-IRCCS Histological diversity of breast adenocarcinomas Different histological types are defined according to specific
More informationDuctal Proliferations of the Breast: The Good, the Bad, and the Ugly
Ductal Proliferations of the Breast: The Good, the Bad, and the Ugly Melinda F. Lerwill, MD CRITERIA FOR DISTINGUISHING LOW-GRADE DUCTAL CARCINOMA IN SITU FROM USUAL DUCTAL HYPERPLASIA CYTOLOGY Low-grade
More informationPapillary Lesions of the Breast
Papillary Lesions of the Breast Laura C. Collins, M.D. Associate Professor of Pathology Associate Director, Division of Anatomic Pathology Beth Israel Deaconess Medical Center and Harvard Medical School
More informationProliferative Breast Disease: implications of core biopsy diagnosis. Proliferative Breast Disease
Proliferative Breast Disease: implications of core biopsy diagnosis Jean F. Simpson, M.D. Breast Pathology Consultants, Inc. Nashville, TN Proliferative Breast Disease Must be interpreted in clinical and
More informationUpdate in Salivary Gland Pathology. Benjamin L. Witt University of Utah/ARUP Laboratories February 9, 2016
Update in Salivary Gland Pathology Benjamin L. Witt University of Utah/ARUP Laboratories February 9, 2016 Objectives Review the different appearances of a selection of salivary gland tumor types Establish
More informationCASE REPORT Malignant transformation of breast ductal adenoma: a diagnostic pitfall
Malaysian J Pathol 2015; 37(3) : 281 285 CASE REPORT Malignant transformation of breast ductal adenoma: a diagnostic pitfall Hiroko HAYASHI, Hiroshi OHTANI,* Junzo YAMAGUCHI,** and Isao SHIMOKAWA Department
More informationCASE REPORT Fine needle aspiration cytology of neuroendocrine carcinoma of the breast - a case report and review of literature
Malaysian J Pathol 2008; 30(1) : 57 61 CASE REPORT Fine needle aspiration cytology of neuroendocrine carcinoma of the breast - a case report and review of literature KADIR Abdul AR MBBS, IYENGAR Krishnan
More informationCLINICAL SIGNIFICANCE OF BENIGN EPITHELIAL CHANGES
Papillomas. Papillomas are composed of multiple branching fibrovascular cores, each having a connective tissue axis lined by luminal and myoepithelial cells ( Fig. 23-11 ). Growth occurs within a dilated
More informationPresentation material is for education purposes only. All rights reserved URMC Radiology Page 1 of 98
Presentation material is for education purposes only. All rights reserved. 2011 URMC Radiology Page 1 of 98 Radiology / Pathology Conference February 2011 Brooke Koltz, Cytopathology Resident Presentation
More informationSolid pseudopapillary tumour of the pancreas: Report of five cases
ISPUB.COM The Internet Journal of Pathology Volume 8 Number 2 Solid pseudopapillary tumour of the pancreas: Report of five cases P Srilatha, V Manna, P Kanthilatha Citation P Srilatha, V Manna, P Kanthilatha..
More informationUniversity Journal of Pre and Para Clinical Sciences
ISSN 2455 2879 Volume 2 Issue 1 2016 Metaplastic carcinoma breast a rare case report Abstract : Metaplastic carcinoma of the breast is a rare malignancy with two distinct cell lines described as a breast
More informationNeuroendocrine neoplasms of the lung
Neuroendocrine neoplasms of the lung M Papotti, L Righi, & M Volante University of Turin at San Luigi Hospital TORINO NETs OF THE LUNG Menu - Spectrum of NE lung tumors - CARCINOID TUMORS - SCLC /LCNEC
More informationPancreatitis: A Potential Pitfall in Endoscopic Ultrasound Guided Pancreatic FNA
Pancreatitis: A Potential Pitfall in Endoscopic Ultrasound Guided Pancreatic FNA Jack Yang, MD Department of Pathology, Medical University of South Carolina Objectives Understand the indication of EUS
More informationAmerican Journal of Cancer Case Reports. Invasive Papillary Carcinoma of Male Breast: A Rare Case Report
American Journal of Cancer Case Reports http://ivyunion.org/index.php/ajccr SantraAetal. American Journal of Cancer Case Reports 2014, 3:56-61 Page 1 of 6 Vol 3 Article ID 20140617, 6 pages Case Report
More informationSalivary Glands 3/7/2017
Salivary Glands 3/7/2017 Goals and objectives Focus on the entities unique to H&N Common board type facts Information for your future practice Salivary Glands Salivary Glands Major gland. Paratid. Submandibular.
More informationEnterprise Interest None
Enterprise Interest None B3 lesions of the breast What are they at surgery? Case 4 Edi Brogi MD PhD Attending Pathologist - Director of Breast Pathology Memorial Sloan Kettering Cancer Center New York
More informationLow-Grade Periductal Stromal of Breast: a case report
Low-Grade Periductal Stromal of Breast: a case report Rosanna Nenna 1 Cosimo Damiano Inchingolo 1 Domenico Palmieri 2 Annalisa De Lucia 1 Giusy Elicio 1 Pina Miscioscia 1 ( 1 ) U.O.C. di Anatomia Patologica,
More informationFlat Epithelial Atypia
Flat Epithelial Atypia Richard Owings, M.D. University of Arkansas for Medical Sciences Department of Pathology Flat epithelial atypia can be a difficult lesion May be a subtle diagnosis Lots of changes
More informationGOBLET CELL CARCINOID. Hanlin L. Wang, MD, PhD University of California Los Angeles
GOBLET CELL CARCINOID Hanlin L. Wang, MD, PhD University of California Los Angeles Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to
More informationGOBLET CELL CARCINOID
GOBLET CELL CARCINOID Hanlin L. Wang, MD, PhD University of California Los Angeles Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to
More informationMaram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine
Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine The most common non-skin malignancy of women 2 nd most common cause of cancer deaths in women, following
More informationCase 1. ACCME/Disclosure. Clinical History. Dr. Mulligan has nothing to disclose
Breast Evening Specialty Conference USCAP, 2016 Case 1 Anna Marie Mulligan University Health Network, Toronto University of Toronto ACCME/Disclosure Dr. Mulligan has nothing to disclose Clinical History
More informationNeuroendocrine Lung Tumors Myers
Diagnosis and Classification of Neuroendocrine Lung Tumors Jeffrey L. Myers, M.D. A. James French Professor Director, Anatomic Pathology & MLabs University of Michigan, Ann Arbor, MI myerjeff@umich.edu
More informationBreast Pathology. Breast Development
Breast Pathology Lecturer: Hanina Hibshoosh, M.D. Reading: Kumar, Cotran, Robbins, Basic Pathology, 6th Edition, pages 623-635 Breast Development 5th week - thickening of the epidermis - milk line 5th
More informationLUNG CANCER PATHOLOGY: UPDATE ON NEUROENDOCRINE LUNG TUMORS
LUNG CANCER PATHOLOGY: UPDATE ON NEUROENDOCRINE LUNG TUMORS William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering Cancer Center New York, NY PULMONARY NE TUMORS CLASSIFICATION
More informationBreast pathology. 2nd Department of Pathology Semmelweis University
Breast pathology 2nd Department of Pathology Semmelweis University Breast pathology - Summary - Benign lesions - Acute mastitis - Plasma cell mastitis / duct ectasia - Fat necrosis - Fibrocystic change/
More informationIntraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance
& 2006 USCAP, Inc All rights reserved 0893-3952/06 $30.00 www.modernpathology.org Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance Charles C Guo 1 and
More informationMammary analogue secretory carcinoma of salivary gland A case report of new entity
Case Report Mammary analogue secretory carcinoma of salivary gland A case report of new entity Vaibhav Bhika Bari 1*, Sandhya Unmesh Bholay 2 1 Assistant Professor, 2 Associate Professor Rajiv Gandhi Medical
More information6/3/2010. Outline of Talk. Lobular Breast Cancer: Definition of lobular differentiation. Common Problems in Diagnosing LCIS in Core Biopsies
Outline of Talk Lobular Breast Cancer: Common Problems in Diagnosing LCIS in Core Biopsies Definition of lobular differentiation Variants of LCIS that: carry risk for unsampled invasive cancer mimic DCIS
More informationDisclosures 5/27/2012. Outline of Talk. Outline of Talk. When Is LCIS Clinically Significant? Classic LCIS. Classic LCIS
When Is LCIS Clinically Significant? Disclosures I have nothing to disclose Yunn-Yi Chen, MD, PhD Professor Outline of Talk Outline of Talk Classic LCIS Classic LCIS Definition of lobular differentiation
More informationSurgical Pathology Issues of Practical Importance
Surgical Pathology Issues of Practical Importance Anne Moore, MD Medical Oncology Syed Hoda, MD Surgical Pathology The pathologist is central to the team approach needed to manage the patient with breast
More informationEpithelial Columnar Breast Lesions: Histopathology and Molecular Markers
29th Annual International Conference Advances in the Application of Monoclonal Antibodies in Clinical Oncology and Symposium on Cancer Stem Cells 25 th -27t h June, 2012, Mykonos, Greece Epithelial Columnar
More informationInvasive Papillary Breast Carcinoma
410 This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license), applicable to the online version of the
More informationPathological Classification of Hepatocellular Carcinoma
3 rd APASL Single Topic Conference: HCC in 3D Pathological Classification of Hepatocellular Carcinoma Glenda Lyn Y. Pua, M.D. HCC Primary liver cancer is the 2 nd most common cancer in Asia HCC is the
More informationNote: The cause of testicular neoplasms remains unknown
- In the 15- to 34-year-old age group, they are the most common tumors of men. - Tumors of the testis are a heterogeneous group of neoplasms that include: I. Germ cell tumors : 95%; all are malignant.
More informationEnterprise Interest None
Enterprise Interest None What are triple negative breast cancers? A synopsis of their histological patterns Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology,
More informationObjectives. Atypical Glandular Cells. Atypical Endocervical Cells. Reactive Endocervical Cells
2013 California Society of Pathologists 66 th Annual Meeting San Francisco, CA Atypical Glandular Cells to Early Invasive Adenocarcinoma: Cervical Cytology and Histology Christina S. Kong, MD Associate
More informationOncocytic carcinoma: A rare malignancy of the parotid gland
ISPUB.COM The Internet Journal of Pathology Volume 8 Number 2 Oncocytic carcinoma: A rare malignancy of the parotid gland K Mardi, J Sharma Citation K Mardi, J Sharma.. The Internet Journal of Pathology.
More informationColumnar Cell Lesions. Columnar Cell Lesions and Flat Epithelial Atypia
Columnar Cell Lesions and Stuart J. Schnitt, M.D. Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA, USA Columnar Cell Lesions Lesions characterized by columnar epithelial cells
More informationACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI
USCAP GU Specialty Conference Case 3 March 2016 L. Priya Kunju, M.D. University of Michigan Health System Ann Arbor, MI University of Michigan Health System ACCME/Disclosures The USCAP requires that anyone
More informationCase Report Basaloid ductal carcinoma in situ arising in salivary gland metaplasia of the breast: a case report
Int J Clin Exp Pathol 2014;7(9):6370-6374 www.ijcep.com /ISSN:1936-2625/IJCEP0001480 Case Report Basaloid ductal carcinoma in situ arising in salivary gland metaplasia of the breast: a case report Eun
More informationPapillary Lesions of the breast
Papillary Lesions of the breast Emad Rakha Professor of Breast Pathology The University of Nottingham Papillary lesions of the breast are a heterogeneous group of disease, which are characterised by neoplastic
More informationInternational Society of Gynecological Pathologists Symposium 2007
International Society of Gynecological Pathologists Symposium 2007 Anais Malpica, M.D. Department of Pathology The University of Texas M.D. Anderson Cancer Center Grading of Ovarian Cancer Histologic grade
More informationCase Report Endocrine Mucin-Producing Sweat Gland Carcinoma, a Histological Challenge
Hindawi Volume 2017, Article ID 6343709, 4 pages https://doi.org/10.1155/2017/6343709 Case Report Endocrine Mucin-Producing Sweat Gland Carcinoma, a Histological Challenge Mary Anne Brett, Samih Salama,
More informationFine-Needle Aspiration Cytology of Low-Grade Cribriform Cystadenocarcinoma with Many Psammoma Bodies of the Salivary Gland
The Korean Journal of Pathology 2013; 47: 481-485 CASE STUDY Fine-Needle Aspiration Cytology of Low-Grade Cribriform Cystadenocarcinoma with Many Psammoma Bodies of the Salivary Gland Ji Yun Jeong Dongbin
More informationProblem 1: Differential of Neuroendocrine Carcinoma 3/23/2017. Disclosure of Relevant Financial Relationships
Differential of Neuroendocrine Carcinoma Alain C. Borczuk,MD Weill Cornell Medicine Disclosure of Relevant Financial Relationships USCAP requires that all faculty in a position to influence or control
More informationROBINSON CYTOLOGICAL GRADING OF BREAST CARCINOMA ON FINE NEEDLE ASPIRATION CYTOLOGY- AN OVERVIEW
Page564 Research Article Biological Sciences ROBINSON CYTOLOGICAL GRADING OF BREAST CARCINOMA ON FINE NEEDLE ASPIRATION CYTOLOGY- AN OVERVIEW Charusheela Rajesh Gore, Chandanwale Shirish S, Ruchika Aggarwal,
More informationUrinary Bladder: WHO Classification and AJCC Staging Update 2017
Urinary Bladder: WHO Classification and AJCC Staging Update 2017 Houston Society of Clinical Pathologists 58 th Annual Spring Symposium Houston, TX April 8, 2017 Jesse K. McKenney, MD Classification
More informationColumnar Cell Lesions
Columnar Cell Lesions Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Question? Columnar cell lesions are: a) Annoying lesions
More informationTreatment options for the precancerous Atypical Breast lesions. Prof. YOUNG-JIN SUH The Catholic University of Korea
Treatment options for the precancerous Atypical Breast lesions Prof. YOUNG-JIN SUH The Catholic University of Korea Not so benign lesions? Imaging abnormalities(10% recall) lead to diagnostic evaluation,
More informationPRELIMINARY CYTOLOGIC DIAGNOSIS: Suspicious for Acinic Cell Carcinoma. Cell Block: Immunohistochemical Studies CYTOLOGIC DIAGNOSIS:
1 PRELIMINARY CYTOLOGIC DIAGNOSIS: Suspicious for Acinic Cell Carcinoma. Cell Block: Immunohistochemical Studies GCDFP-15 S-100 CYTOLOGIC DIAGNOSIS: Consistent with mammary analogue secretory carcinoma.
More informationARTHUR PURDY STOUT SOCIETY COMPANION MEETING: DIFFICULT NEW DIFFERENTIAL DIAGNOSES IN PROSTATE PATHOLOGY. Jonathan I. Epstein.
1 ARTHUR PURDY STOUT SOCIETY COMPANION MEETING: DIFFICULT NEW DIFFERENTIAL DIAGNOSES IN PROSTATE PATHOLOGY Jonathan I. Epstein Professor Pathology, Urology, Oncology The Reinhard Professor of Urological
More informationDiagnostic problems in uterine smooth muscle tumors
Diagnostic problems in uterine smooth muscle tumors Marina Kos Ljudevit Jurak Clinical Department of Pathology, Clinical Hospital Center Sestre milosrdnice, Zagreb Institute of Pathology, University of
More informationProtocol for the Examination of Biopsy Specimens From Patients With Invasive Carcinoma of the Breast
Protocol for the Examination of Specimens From Patients With Invasive Carcinoma of the Breast Version: BreastInvasive 1.0.0.0 Protocol Posting Date: February 2019 Accreditation Requirements The use of
More informationMody. AIS vs. Invasive Adenocarcinoma of the Cervix
Common Problems in Gynecologic Pathology Michael T. Deavers, M.D. Houston Methodist Hospital, Houston, Texas Common Problems in Gynecologic Pathology Adenocarcinoma in-situ (AIS) of the Cervix vs. Invasive
More informationA 53 year-old woman with a lung mass, right hilar mass and mediastinal adenopathy.
November 2015 Case of the Month A 53 year-old woman with a lung mass, right hilar mass and mediastinal adenopathy. Contributed by: Rasha Salama, M.D., IU Department of Pathology and Laboratory Medicine
More informationCase 2. Dr. Sathima Natarajan M.D. Kaiser Permanente Medical Center Sunset
Case 2 Dr. Sathima Natarajan M.D. Kaiser Permanente Medical Center Sunset History 24 year old male presented with a 3 day history of right flank pain, sharp in nature Denies fever, chills, hematuria or
More informationFNA of Thyroid. Toward a Uniform Terminology With Management Guidelines. NCI NCI Thyroid FNA State of the Science Conference
FNA of Thyroid NCI NCI Thyroid FNA State of the Science Conference Toward a Uniform Terminology With Management Guidelines Thyroid Thyroid FNA Cytomorphology NCI Thyroid FNA State of the Science Conference
More informationCytological Sub-classification of Lung Cancer: Morphologic and Molecular Characteristics. Mercè Jordà, University of Miami
Cytological Sub-classification of Lung Cancer: Morphologic and Molecular Characteristics Mercè Jordà, University of Miami Mortality Lung cancer is the most frequent cause of cancer incidence and mortality
More informationGOBLET CELL CARCINOID. Hanlin L. Wang, MD, PhD University of California Los Angeles
GOBLET CELL CARCINOID Hanlin L. Wang, MD, PhD University of California Los Angeles hanlinwang@mednet.ucla.edu Goblet cell carcinoid (GCC) is a unique type of mixed endocrine-exocrine neoplasm, almost exclusively
More informationMedullary Thyroid Carcinoma. This case was provided by Treant Hospital, Bethesda, Hoogeveen, The Netherlands
Medullary Thyroid Carcinoma This case was provided by Treant Hospital, Bethesda, Hoogeveen, The Netherlands ADS-01504 Rev. 001 2016 Hologic, Inc. All rights reserved. Overview Medullary Thyroid Carcinoma
More informationContents 1 The Windows of Susceptibility to Breast Cancer 2 The So Called Pre-Neoplastic Lesions and Carcinoma In Situ
Contents 1 The Windows of Susceptibility to Breast Cancer... 1 1.1 Introduction... 1 1.2 Risk Factor and Etiological Agents... 2 1.3 The Concept of the Windows of Susceptibility to Carcinogenesis... 5
More informationDuctal Carcinoma in Situ. Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA
Ductal Carcinoma in Situ Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Definition of DCIS WHO 2012 A neoplastic proliferation
More informationPapillary Lesions of the Breast
Papillary Lesions of the Breast Texas Society of Pathologists 2013 Laura C. Collins, M.D. Associate Professor of Pathology Associate Director, Division of Anatomic Pathology Beth Israel Deaconess Medical
More informationInternational Journal of Pharma and Bio Sciences CHROMOPHOBE VARIANT OF RENAL CELL CARCINOMA MASQUARDING AS RENAL ONCOCYTOMA ON CYTOLOGY.
Case Report Pathology International Journal of Pharma and Bio Sciences ISSN 0975-6299 CHROMOPHOBE VARIANT OF RENAL CELL CARCINOMA MASQUARDING AS RENAL ONCOCYTOMA ON CYTOLOGY. DR.MAMATHA K*, DR. ARAKERI
More informationDIAGNOSTIC SLIDE SEMINAR: PART 1 RENAL TUMOUR BIOPSY CASES
DIAGNOSTIC SLIDE SEMINAR: PART 1 RENAL TUMOUR BIOPSY CASES Dr. Andrew J. Evans MD, PhD, FACP, FRCPC Consultant in Genitourinary Pathology University Health Network, Toronto, ON Case 1 43 year-old female,
More information57th Annual HSCP Spring Symposium 4/16/2016
An Unusual Malignant Spindle Cell Lesion to Involve the Breast Erinn Downs-Kelly, D.O. Associate Professor of Pathology University of Utah & ARUP Laboratories No disclosures Case 39 y/o female with no
More informationCase history: Figure 1. H&E, 5x. Figure 2. H&E, 20x.
1 Case history: A 49 year-old female presented with a 5 year history of chronic anal fissure. The patient s past medical history is otherwise unremarkable. On digital rectal examination there was a very
More informationBenign Mimics of Malignancy in Breast Pathology
Arthur Purdy Stout Society of Surgical Pathologists Companion Meeting Benign Mimics of Malignancy in Breast Pathology Stuart J. Schnitt, M.D. Beth Israel Deaconess Medical Center and Harvard Medical School,
More informationPSA. HMCK, p63, Racemase. HMCK, p63, Racemase
Case 1 67 year old male presented with gross hematuria H/o acute prostatitis & BPH Urethroscopy: small, polypoid growth with a broad base emanating from the left side of the verumontanum Serum PSA :7 ng/ml
More informationSalivary gland tumor cytologic and histologic correlation: Algorithmic and risk stratification based approaches
Salivary gland tumor cytologic and histologic correlation: Algorithmic and risk stratification based approaches Christopher C. Griffith, MD, PhD Raja R. Seethala, MD 1. Salivary gland tumor cytology: A
More informationCase Report A case of matrix-producing carcinoma of the breast with micoglandular adenosis and review of literature
Int J Clin Exp Pathol 2015;8(7):8568-8572 www.ijcep.com /ISSN:1936-2625/IJCEP0010093 Case Report A case of matrix-producing carcinoma of the breast with micoglandular adenosis and review of literature
More informationMalignant transformation of fibroadenomas
Malignant transformation of fibroadenomas Poster No.: C-2503 Congress: ECR 2013 Type: Educational Exhibit Authors: L. N. Elias, M. A. Rudner, L. M. Yano, P. C. Moraes, Y. 1 1 1 1 1 1 2 1 2 Chang, M. B.
More informationMalignant Phyllodes tumor with necrosis a rare case report
Quest Journals Journal of Medical and Dental Science Research Volume 1 ~ Issue 1 (2014) pp: 01-06 ISSN(Online) : 2394-076X ISSN (Print):2394-0751 www.questjournals.org Research Paper Malignant Phyllodes
More informationSynchronous squamous cell carcinoma of the breast. and invasive lobular carcinoma
Sentani K et al. 1 Letter to the editor Synchronous squamous cell carcinoma of the breast and invasive lobular carcinoma Kazuhiro Sentani, 1 Takashi Tashiro, 2 Naohide Oue, 1 Wataru Yasui 1 1 Department
More informationFollicular Derived Thyroid Tumors
Follicular Derived Thyroid Tumors Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology Chair of Pathology and Laboratory Medicine University of Arkansas for Medical Sciences
More informationUpdate on 2015 WHO Classification of Lung Adenocarcinoma 1/3/ Mayo Foundation for Medical Education and Research. All rights reserved.
1 Our speaker for this program is Dr. Anja Roden, an associate professor of Laboratory Medicine and Pathology at Mayo Clinic as well as consultant in the Anatomic Pathology Laboratory and co-director of
More informationRare types of breast carcinoma
Open Med. 2015; 10: 92-96 Research Article Open Access Daiva Gudaviciene*, Laura Steponaviciene, Raimundas Meskauskas, Giedre Smailyte, Eduardas Aleknavicius Rare types of breast Abstract: Breast cancer
More informationACCME/Disclosures. Cribriform Lesions of the Prostate. Case
Cribriform Lesions of the Prostate Ming Zhou, MD, PhD Departments of Pathology and Urology New York University Langone Medical Center New York, NY Ming.Zhou@NYUMC.ORG ACCME/Disclosures The USCAP requires
More information04/09/2018. Salivary Gland Pathology in the Molecular Era Old Friends, Old Foes, & New Acquaintances
Salivary Gland Pathology in the Molecular Era Old Friends, Old Foes, & New Acquaintances Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology Chair of Pathology and Laboratory
More informationSmall Cell Carcinoma ex-pleomorphic Adenoma of the Parotid Gland
Head and Neck Pathol (2012) 6:502 506 DOI 10.1007/s12105-012-0376-1 CASE REPORT Small Cell Carcinoma ex-pleomorphic Adenoma of the Parotid Gland Ashley Cimino-Mathews Brian M. Lin Steven S. Chang Kofi
More information3/27/2017. Pulmonary Pathology Specialty Conference. Disclosure of Relevant Financial Relationships. Clinical History:
Pulmonary Pathology Specialty Conference Saul Suster, M.D. Medical College of Wisconsin Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position
More information